Category: Latest News
-
AEye Apollo Lidar Selected for Lunar Outpost’s Pegasus Lunar Terrain Vehicle
The multi-million-dollar contract brings AEye into the space mobility market, expanding Apollo lidar beyond automotive, defense and industrial applications into lunar navigation. Key Investor Takeaways Why LIDR Stock Is in Focus AEye has entered the space mobility market after Lunar Outpost selected its Apollo long-range lidar for integration into the Pegasus Lunar Terrain Vehicle. The…
-
bioAffinity Technologies Advances CyPath Lung for Post-Treatment Lung Cancer Surveillance
The company is evaluating an additional application for CyPath Lung that could complement CT imaging when monitoring lung cancer survivors for recurrence or new primary cancers. Key Investor Takeaways Why BIAF Stock Is in Focus bioAffinity Technologies is advancing the potential use of CyPath Lung as a surveillance tool for patients who have completed curative-intent…
-
NUBURU Advances Tekne Acquisition as Adjusted Active Order Value Reaches $135.4 Million
The proposed 70% Tekne acquisition is now expected to close in the first half of October as NUBURU moves from assembling its Defense & Security platform toward integrating its operating capabilities. Key Investor Takeaways Why BURU Stock Is in Focus NUBURU has provided a more specific closing timetable for its proposed acquisition of a 70%…
-
Wetour Robotics Demonstrates sEMG-Vision System for Physical AI Training
The Orchestra development demonstration combines muscle-activity sensing with first-person vision to capture force-related information and maintain hand data when cameras lose visibility. Key Investor Takeaways Why WETO Stock Is in Focus Wetour Robotics has released a development demonstration of Orchestra, its Physical AI platform combining surface electromyography, or sEMG, with first-person vision to address two…
-
ONAR Advances Largest Potential Acquisition With $1.25 Million in Down Payments
The company has increased its financial commitment to the proposed transaction while securing bridge funding from lenders involved in its planned $15 million financing and retiring another convertible note. Key Investor Takeaways Why ONAR Stock Is in Focus ONAR has advanced its largest potential acquisition by making a second $250,000 down payment toward the purchase…
-
Reitar Logtech Eliminates $2.2 Million Convertible Notes, Removing Legacy Financing Overhang
The full conversion of the December 2025 notes removes Reitar Logtech’s outstanding senior promissory note obligations without requiring a cash repayment, while preserving liquidity for its growth strategy. Key Investor Takeaways Why RITR Stock Is in Focus Reitar Logtech has completed the full conversion of two senior promissory notes originally issued in December 2025, eliminating…
-
Med-X targets global pest control market with Nature-Cide
Med-X CEO Matthew Mills discusses Nature-Cide, pest control partnerships, global expansion and the company’s planned Nasdaq listing.
-
Micron shares fall 1.8% following Taiwan incentive pay report
Micron Technology (NASDAQ:MU) shares fell 1.8% in pre-market trading on Tuesday following a report concerning employee incentive payments at the company’s Taiwan operations, while technology stocks also faced broader pressure from higher interest rates. Taiwan’s Liberty Times reported that Micron plans to introduce its highest incentive payment package to date for employees in Taiwan amid…
-
QC Ware and IonQ demonstrate hybrid quantum-classical chemistry workflow
QC Ware and IonQ (NYSE:IONQ) announced a technology demonstration of a hybrid quantum-classical chemistry workflow combining QC Ware’s Promethium platform with IonQ’s Forte trapped-ion quantum computer, accessed through Amazon Braket. The demonstration modelled the heme active site of cytochrome P450nor, an enzyme in the cytochrome P450 superfamily involved in nitric oxide reduction. Members of the…
-
Alumis Phase 2b lupus trial misses primary and secondary endpoints
Alumis Inc. (Nasdaq: ALMS) said its Phase 2b LUMUS trial evaluating envudeucitinib in patients with moderate-to-severe systemic lupus erythematosus (SLE) did not meet its primary or secondary endpoints in the overall study population. The trial enrolled 408 patients who received one of three doses of envudeucitinib or placebo over 48 weeks. The primary endpoint assessed…